Citations

Showing 10 of 108152 citations.

Progression of Preclinical Heart Failure: A Description of Stage A and B Heart Failure in a Community Population
Young, Kathleen A. , Scott, Christopher G. , Rodeheffer, Richard J. , Chen, Horng H. , Scott, Christopher

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 6, 2021 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/circoutcomes.120.007216 | PMID 33951931 Get It

Background: The aims of this study are to evaluate the rate of progression of preclinical (Stage A and B) heart failure, identify associated characteristics, and evaluate long-term outcomes. Methods: Retrospective review of the Olmsted County Heart Function Study. Individuals categorized as Stage A or B heart failure at initial visit that returned for a second visit 4 years later were included. Logistic regression analyses evaluated group differences with adjustment for age and sex. Results: At visit 1, 413 (32%) individuals were classified as Stage A and 413 (32%) as Stage B. By visit 2, 146 (35%) individuals from Stage A progressed with the vast majority (n=142) progressing to Stage B. In comparison, a total of 23 (6%) individuals progressed from Stage B. A greater rate of progression was seen for Stage A compared with Stage B (8.7 per 100 person-years [95% CI, 7.4–10.2] versus 1.4 per 100 person-years [95% CI, 0.9–2.1]; P <0.001). NT-proBNP correlated with progression for Stage B ( P =0.01), but not for Stage A ( P =0.39). A multivariate model found female sex (odds ratio, 1.65 [95% CI, 1.05–2.58]; P =0.03), increased E/e’ (odds ratio, 1.13 [95% CI, 1.02–1.26], P =0.02), and beta blocker use (odds ratio, 2.19 [95% CI, 1.25–3.82], P =0.006) were associated with progression for Stage A. There was a signal that cardiovascular mortality was higher in individuals who progressed, although not statistically significant ( P =0.06 for Stage A and P =0.05 for Stage B). Conclusions: There is significant progression of preclinical heart failure in a community population, with progression rates higher for Stage A. NT-proBNP correlated with progression for Stage B, but not for Stage A. No statistically significant differences in long-term outcomes were seen. Study results have clinical implications important to help guide future heart failure screening and prevention strategies.
Genetic architecture of smoking: Evaluating rare variant contribution from deep whole-genome sequencing of up to 26,000 individuals
Jang, Seon-Kyeong , Arnett, Donna K. , Becker, Diane M. , Bis, Joshua C. , Bleecker, Eugene R., Fingerlin, Tasha E. , Haessler, Jeffrey, Heckbert, Susan R. , Hokanson, John E. , Judy, Renae , Justice, Anne E. , Kaplan, Robert C. , Kim, Wonji , Gladwin, Mark T. , Melander, Olle , Meyers, Deborah A. , Peljto, Anna L. , Qiao, Dandi , Reed, Robert M. , Reiner, Alex P. , Silverman, Edwin K. , Smith, Nicholas L. , Smith, Gustav, Smith, Albert V. , Tang, Weihong, Gordeuk, Victor R. , Yanek, Lisa R. , Yang, Ivana V. , Young, Kendra A. , Vrieze, Scott , Martin, Lisa , Smith, Albert V , Arnett, Donna K , Evans, Luke M. , Fialkowski, Allison , Blangero, John , Brody, Jennifer A. , Cupples, L. Adrienne , Damrauer, Scott M , David, Sean P. , Andrade, Mariza de , Gharib, Sina A. , Glahn, David C , Hwang, Shih‐Jen , Hyman, Matthew Craig , Kooperberg, Charles , Levy, Dan , Loos, Ruth J. F. , Manichaikul, Ani , Martin, Lisa W. , Nouraie, Mehdi , North, Kari E. , Oelsner, Elizabeth C. , Preuss, Michael , Psaty, Bruce M. , Rader, Daniel J , Rich, Stephen S. , Rotter, Jerome I. , Schwartz, David A. , Shadyab, Aladdin H , Taylor, Kent D. , Vasan, Ramachandran S. , Wang, Zhe , Wiggins, Kerri L. , Young, Kristin L. , Zhang, Yingze , Liu, Dajiang J. , Keller, Matthew C.

Mayo Clinic

No container title available | May 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-475149/v1 Get It

Abstract Background Across complex traits, common variants explain only a modest amount of variance, with SNP-heritability consistently below heritability estimates from close relatives. Here, we examined the contribution of rare variant to tobacco use risk in up to 26,000 individuals of European ancestry in the Trans-Omics for Precision Medicine (TOPMed) program with whole genome sequence (WGS;~30X coverage).Method We grouped about 35 million genetic variants by their minor allele frequencies (MAF) and linkage disequilibrium (LD) and estimated SNP-heritability for age of smoking initiation (N = 14,747), cigarettes smoked per day (N = 15,425), smoking cessation (N = 17,871) and initiation (N = 26,340) using linear mixed model. Rare variant population structure is detected and adjusted for by permutation procedure. We estimated an upper bound for narrow-sense heritability for tobacco use using available pedigrees consisting of close relatives in TOPMed.Results Rare variants with MAF 0.1–0.01%, mostly from non-protein altering region, accounted for 26% of variation in age of initiation and 15% for cessation. Follow-up analysis indicated that about one-third of these rare variants contribtion is potentially confounded with rare variants structure even after adjusting for principal components. After further conservative adjustment of population structure, we estimated SNP-based heritability to be 0.21 (SE = 0.08) for age of initiation, 0.15 (0.06) for cigarettes per day, 0.21 (0.09) for cessation, and 0.24 (0.07) for initiation, 1.8–4.5 times higher than previous SNP-based estimates. Our pedigree-based upper-bound for SNP-based heritability ranged from 0.18–0.35.Conclusion The substantial contribution of rare variants for several smoking phenotypes sheds light on the missing heritability and genetic etiology of tobacco use. It also informs fine-mapping strategies since the majority of the rare variant contribution was located in non-coding regulatory regions.
Real-time intracardiac echocardiography validation of saline-enhanced radiofrequency needle-tip ablation: lesion characteristics and gross pathology correlation
Dickow, Jannis , Wang, Songyun , Suzuki, Atsushi , Imamura, Kimitake, Parker, Kay D., Newman, Laura K. , Monahan, Kristi H. , Rettmann, Maryam E. , Curley, Michael , Packer, Douglas L. , Lehmann, H. Immo

Mayo Clinic

EP Europace | May 5, 2021 | Volume: 23 | Issue: 11 | Pages: 1826-1836

10.1093/europace/euab121 | PMID 33993234 Get It

Abstract Aims With the implementation of saline-enhanced radiofrequency (SERF) needle-tip ablation, real-time validation of lesion formation is needed for the controllable creation of transmural lesions. The aim of the study was to analyse the ability of two-dimensional intracardiac echocardiography (2D-ICE) to guide and validate SERF ablation in real-time. Methods and results Fifty-six SERF energy deliveries at left ventricular sites of 11 dogs guided by 2D-ICE were analysed (power: 15–50 W; time: 25–120 s; irrigation saline: 60°C with 10 mL/min flow rate). Catheter tip/tissue orientation and lesion formation could be well detected by 2D-ICE in 49 (87.5%) energy deliveries. Gross pathology analysis confirmed excellent 2D-ICE lesion localization, the ability to detect transmural lesions (70% sensitivity, 47% specificity) and positive correlation between 2D-ICE and the corresponding gross pathology measurements of ‘maximal lesion depth’; (repeated measures correlation: rrm = 0.43, P = 0.012) and ‘depth at maximal lesion width’ (D@MW; rrm = 0.51, P = 0.003). The median angle between SERF catheter tip and endocardium was 76° [interquartile range (IQR) 58–83°]. The more perpendicular the catheter tip/tissue orientation was the deeper D@MW (rrm = 0.32, P = 0.045). Grade 3 microbubbles on 2D-ICE during ablation, indicating inadequate catheter tip/tissue contact, was associated with smaller lesion volumes than with Grade 1 microbubbles (284.8 mm3 [IQR 151.3–343.1] vs. 2114.1 mm3 [IQR 1437.0–3026.3], P &lt; 0.001). Conclusion With excellent lesion localization and a 70% detection rate of transmural lesions, 2D-ICE is well suited to validate SERF ablation lesion formation in real-time. The catheter tip/tissue angle impacts the lesion formation and through perpendicular catheter positioning, deeper intramural areas of the myocardium can be reached.
The voltage-gated proton channel Hv1 promotes microglia-astrocyte communication and neuropathic pain after peripheral nerve injury
Peng, Jiyun , Yi, Min‐Hee , McEwan, Sara A. , Wu, Gongxiong, Ren, Yi , Jeong, Heejin, Zheng, Jiaying , Ganatra, Shashank , Richardson, Jason R. , Oh, Seog Bae , Wu, Long‐Jun

Mayo Clinic

No container title available | May 5, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-479825/v1 Get It

Abstract Activation of spinal cord microglia contributes to the development of peripheral nerve injury-induced neuropathic pain. However, the molecular mechanisms underlying microglial function in neuropathic pain are not fully understood. We identified that the voltage-gated proton channel Hv1, which is functionally expressed in spinal microglia, was significantly increased after spinal nerve transection (SNT). Hv1 mediated voltage-gated proton currents in spinal microglia and mice lacking Hv1 (Hv1 KO) display attenuated pain hypersensitivities after SNT compared with wildtype (WT) mice. In addition, microglial production of reactive oxygen species (ROS) and subsequent astrocyte activation in the spinal cord was reduced in Hv1 KO mice after SNT. Cytokine screening and immunostaining further revealed that IFN-γ expression was compromised in spinal astrocytes in Hv1 KO mice. These results demonstrate that Hv1 proton channel contributes to microglial ROS production, astrocyte activation, IFN-γ upregulation, and subsequent pain hypersensitivities after SNT. This study suggests Hv1-dependent microglia-astrocyte communication in pain hypersensitivities and identifies Hv1 as a novel therapeutic target for alleviating neuropathic pain.
International consensus to standardise histopathological scoring for small bowel strictures in Crohn’s disease
Gordon, Ilyssa O. , Bokemeyer, Arne , Rosty, Christophe , Robert, Marie E. , Mao, Ren, Borralho, Paula , Pai, Reetesh K. , Odze, Robert D. , Feakins, Roger , Parker, Claire E. , Guizzetti, Leonardo , Nguyen, Tran M , Shackelton, Lisa M. , Sandborn, William J. , Baker, Mark E. , Bruining, David H. , Feagan, Brian G. , Pai, Rish K. , Rieder, Florian , Bettenworth, Dominik , Bokemeyer, Arne , Rosty, Christophe , Mao, Ren , Pai, Reetesh K , Bruining, David, Feagan, B G , Pai, R K , Rieder, Florian , Guizzetti, L , Gordon, Ilyssa O , Srivastava, Amitabh , Hertogh, Gert D. , Valasek, Mark A. , Li, Jiannan , Harpaz, Noam , Jairath, Vipul , Fletcher, Joel G.

Mayo Clinic

Gut | May 5, 2021 | Volume: 71 | Issue: 3 | Pages: 479-486

10.1136/gutjnl-2021-324374 | PMID 33952604 Get It

Objective Effective medical therapy and validated trial outcomes are lacking for small bowel Crohn’s disease (CD) strictures. Histopathology of surgically resected specimens is the gold standard for correlation with imaging techniques. However, no validated histopathological scoring systems are currently available for small bowel stricturing disease. We convened an expert panel to evaluate the appropriateness of histopathology scoring systems and items generated based on panel opinion. Design Modified RAND/University of California Los Angeles methodology was used to determine the appropriateness of 313 candidate items related to assessment of CD small bowel strictures. Results In this exercise, diagnosis of naïve and anastomotic strictures required increased bowel wall thickness, decreased luminal diameter or internal circumference, and fibrosis of the submucosa. Specific definitions for stricture features and technical sampling parameters were also identified. Histopathologically, a stricture was defined as increased thickness of all layers of the bowel wall, fibrosis of the submucosa and bowel wall, and muscularisation of the submucosa. Active mucosal inflammatory disease was defined as neutrophilic inflammation in the lamina propria and any crypt or intact surface epithelium, erosion, ulcer and fistula. Chronic mucosal inflammatory disease was defined as crypt architectural distortion and loss, pyloric gland metaplasia, Paneth cell hyperplasia, basal lymphoplasmacytosis, plasmacytosis and fibrosis, or prominent lymphoid aggregates at the mucosa/submucosa interface. None of the scoring systems used to assess CD strictures were considered appropriate for clinical trials. Conclusion Standardised assessment of gross pathology and histopathology of CD small bowel strictures will improve clinical trial efficiency and aid drug development.
High Achiever: The Incredible True Story of One Addict’s Double Life
Paulson, Deidre

Mayo Clinic

Family Medicine | May 5, 2021 | Volume: 53 | Issue: 5 | Pages: 385-386

10.22454/fammed.2021.577226 Get It

Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
Meermeier, Erin W. , Welsh, Seth J. , Sharik, Meaghen E. , Du, Megan T. , Garbitt, Victoria M. , Shi, Chang‐Xin, Bergsagel, Marco, Chau, Bryant, Wheeler, Matthew L. , Bezman, Natalie, Wang, Feng, Strop, Pavel , Bergsagel, P. Leif , Chesi, Marta , Bergsagel, P. Leif , Riggs, Daniel L. , Chesi, Marta , Meermeier, Erin W , Stein, Caleb K.

Mayo Clinic

Blood Cancer Discovery | May 5, 2021 | Volume: 2 | Issue: 4 | Pages: 354-369

10.1158/2643-3230.bcd-21-0038 | PMID 34258584 Get It

Abstract BCMA/CD3-targeting bispecific antibodies (BsAb) are a recently developed immunotherapy class that shows potent tumor killing activity in multiple myeloma. Here, we investigated a murine BCMA/CD3-targeting BsAb in the immunocompetent Vk*MYC model and its immunomodulatory imide drug (IMiD)–sensitive derivative Vk*MYChCRBN model of multiple myeloma. The BCMA/CD3 BsAb was safe and efficacious in a subset of mice but failed in those with high tumor burden, consistent with clinical reports of BsAb in leukemia. The combination of BCMA/CD3 BsAb with pomalidomide expanded lytic T cells and improved activity even in IMiD-resistant high–tumor burden cases. Yet, survival was only marginally extended due to acute toxicity and T-cell exhaustion, which impaired T-cell persistence. In contrast, the combination with cyclophosphamide was safe and allowed for a tempered proinflammatory response associated with long-lasting complete remission. Concurrent cytotoxic therapy with BsAb actually improved T-cell persistence and function, offering a promising approach to patients with a large tumor burden. Significance: BCMA-targeted therapy induces deep but transient clinical responses. We developed an immunocompetent, IMiD-sensitive genetically engineered mouse model and show that IMiDs potentiate T-cell activation, increasing short-term efficacy of anti-BCMA/CD3 BsAb, but exacerbate T-cell exhaustion. Surprisingly, by reducing tumor burden and depleting regulatory T cells, cyclophosphamide prevents BsAb-induced T-cell exhaustion and promotes long-term multiple myeloma control. See related commentary by Louvet et al., p. 297.
Editorial Comment: Pancreatic CT Protocol With Delayed Phase May Help Detect Small Adenocarcinoma
Alexander, Lauren F. , Alexander, Lauren F

Mayo Clinic

American Journal of Roentgenology | May 5, 2021 | Volume: 217 | Issue: 4 | Pages: 897-897

10.2214/ajr.21.26096 | PMID 33949879 Get It

MRI Staging in an Evolving Management Paradigm for Rectal Cancer, From the AJR Special Series on Cancer Staging
Kaur, Harmeet, Gabriel, Helena, Taggart, Melissa, Kang, Hyunseon C., Konishi, Tsuyoshi, Rauch, Gaiane M., Krishnan, Sunil, Chang, George, Kaur, Harmeet, Gabriel, Helena, Taggart, Melissa, Kang, Hyunseon C., Konishi, Tsuyoshi, Rauch, Gaiane M., Krishnan, Sunil, Chang, George

Mayo Clinic

American Journal of Roentgenology | May 5, 2021 | Volume: 217 | Issue: 6 | Pages: 1282-1293

10.2214/ajr.21.25556 | PMID 33949877 Get It

Acute intrathecal BDNF enhances functional recovery after cervical spinal cord injury in rats
Zhan, Wen-Zhi, Sieck, Gary C. , Gransee, Heather M. , Zhan, Wen‐Zhi, Mantilla, Carlos B.

Mayo Clinic

Journal of Neurophysiology | May 5, 2021 | Volume: 125 | Issue: 6 | Pages: 2158-2165

10.1152/jn.00146.2021 | PMID 33949892 Get It

Brain-derived neurotrophic factor (BDNF) plays an important role in promoting neuroplasticity following unilateral C2 spinal hemisection (C2SH). BDNF was administered intrathecally in rats displaying lack of ipsilateral inspiratory-related diaphragm (DIAm) EMG activity after C2SH. Acute BDNF treatment (30 min) restored eupneic DIAm EMG activity in all treated animals to 78% ± 9% of pre-C2SH level. In addition, acute BDNF treatment increased DIAm EMG amplitude during hypoxia-hypercapnia but had no effect on EMG amplitude during sighs.